Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.69 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18642714 | 1.00 | RIPK1 (0.69) | RIPK1NR1H2NR1H3HCRTR2TSHR | |
| SCHEMBL17114341 | 0.96 | RIPK1 (0.63) | RIPK1NR1H2NR1H3HCRTR2TSHR | |
| SCHEMBL24365782 | 0.96 | RIPK1 (0.63) | RIPK1NR1H2NR1H3HCRTR2TSHR | |
| SCHEMBL7469150 | 0.96 | RIPK1 (0.63) | RIPK1NR1H2NR1H3HCRTR2TSHR | |
| SCHEMBL30281143 | 0.94 | RIPK1 (0.62) | RIPK1NR1H2NR1H3HCRTR2TSHR | |
| Water SCHEMBL27902502 | 0.94 | RIPK1 (0.62) | RIPK1NR1H2NR1H3HCRTR2TSHR | |
| SCHEMBL27504373 | 0.93 | RIPK1 (0.66) | RIPK1NR1H2NR1H3HCRTR2GPR119 | |
| SCHEMBL27830000 | 0.92 | RIPK1 (0.59) | RIPK1NR1H2NR1H3HCRTR2TSHR | |
| SCHEMBL28193156 | 0.90 | RIPK1 (0.56) | RIPK1NR1H2NR1H3HCRTR2TSHR | |
| SCHEMBL1655270 | 0.87 | RIPK1 (0.53) | RIPK1NR1H2NR1H3TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20220213077-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2022-07-07 | — | — | US | disclosed |
| CN-112638373-A | Cyclin-dependent kinase inhibitors | 金耐特生物制药公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020233618-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海有机化学研究所 (CN) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020233618-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海有机化学研究所 (CN) | 2020-11-26 | — | — | WO | disclosed |
| CN-111978311-A | Apoptosis inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2020-11-24 | — | — | CN | disclosed |
| US-10836761-B2 | Cinchonine-derived catalysts and methods of using same | BRANDEIS UNIVERSITY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200048243-A1 | CINCHONINE-DERIVED CATALYSTS AND METHODS OF USING SAME | BRANDEIS UNIVERSITY (US) | 2020-02-13 | — | — | US | disclosed |
| US-9724682-B2 | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724682-B2 | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| CN-1859914-A | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO INC (US) | 2006-11-08 | — | — | CN | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| EP-1023265-B1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HCMV INFECTIONS | BOEHRINGER INGELHEIM CA LTD (CA) | 2003-01-15 | — | — | EP | disclosed |
| US-6211170-B1 | Azetidinone derivatives for the treatment of HCMV infections | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-04-03 | — | — | US | disclosed |
| EP-1023265-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HCMV INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999018073-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HCMV INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | RIPK1 2544/4885NR1H2 586/4885NR1H3 655/4885 |
| US-10836761-B2 | Cinchonine-derived catalysts and methods of using same | MCM2, MCM7, MCM5 | RIPK1 3444/4885NR1H2 1717/4885NR1H3 2061/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | RIPK1 1785/4885NR1H2 424/4885NR1H3 452/4885 |
| US-20200048243-A1 | CINCHONINE-DERIVED CATALYSTS AND METHODS OF USING SAME | MCM2, MCM7, MCM5 | RIPK1 3444/4885NR1H2 1717/4885NR1H3 2061/4885 |
| US-20220213077-A1 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF | LITAF, TNF, BAD | RIPK1 146/4885NR1H2 2085/4885NR1H3 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.